The purpose is to assess the response of add-on therapy, based on CGI-I scale, at 4 weeks, in patients with MDD who had an inadequate disease control with antidepressant medication.
A cross-sectional observational study to describe treatment management of patients with Major Depressive Disorder (MDD) and inadequate response to antidepressants in Greece
Study Type
OBSERVATIONAL
Enrollment
545
Research Site
Arta, Artas, Greece
Research Site
Athens, Attica, Greece
To assess the response of additional therapy by assessment of percentage of patients with CGI-I score ≤ 2
Time frame: At week 4 after the commencement of add-on therapy
Number of consecutive treatments administered for the management of the current MDD episode until the commencement of adjunctive (add-on) medication.
Time frame: At week 4 after the commencement of add-on therapy
Percentage of patients (n, %) with MADRS score ≤ 10 at week 4 following the onset of adjunctive medication
Time frame: At week 4 following the onset of add-on medication
Percentage of patients (n,%) with a change (decrease) in MADRS score be ≥ 50%
Time frame: At week 4 following the initiation of add-on drug therapy.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Research Site
Chaïdári, Attica, Greece
Research Site
Dafni, Attica, Greece
Research Site
Glyfada, Attica, Greece
Research Site
Kifissia, Attica, Greece
Research Site
Koropí, Attica, Greece
Research Site
Marousi, Attica, Greece
Research Site
Nea Makri, Attica, Greece
Research Site
Peristeri, Attica, Greece
...and 17 more locations